Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.31 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.31 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.31 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29183209 | 1.00 | ALDH1A1 (0.33) | ALDH1A1ACHENPC1LMNAMEN1 | |
| SCHEMBL22612643 | 1.00 | ALDH1A1 (0.33) | ALDH1A1ACHENPC1LMNAMEN1 | |
| SCHEMBL21748791 | 1.00 | ALDH1A1 (0.33) | ALDH1A1ACHENPC1LMNAMEN1 | |
| SCHEMBL3116551 | 1.00 | ALDH1A1 (0.33) | ALDH1A1ACHENPC1LMNAMEN1 | |
| SCHEMBL3124376 | 1.00 | ALDH1A1 (0.33) | ALDH1A1ACHENPC1LMNAMEN1 | |
| Hydrochloric Acid SCHEMBL28502789 | 0.98 | GNAI3 (0.33) | ALDH1A1ACHENPC1LMNAMEN1 | |
| Hydrochloric Acid SCHEMBL28502790 | 0.98 | GNAI3 (0.33) | ALDH1A1ACHENPC1LMNAMEN1 | |
| SCHEMBL22496874 | 0.84 | LMNA (0.37) | ALDH1A1ACHENPC1LMNAMEN1 | |
| SCHEMBL2377686 | 0.84 | EPHX2 (0.37) | ALDH1A1NPC1CHRNA7 | |
| SCHEMBL16169058 | 0.84 | EPHX2 (0.37) | ALDH1A1NPC1CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025851-A1 | Modulators of BCL6 as Ligand Directed Degraders | CELGENE CORPORATION (US) | 2024-01-25 | — | — | US | disclosed |
| WO-2023212147-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | CELGENE CORPORATION (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20230192659-A1 | N-(HETEROCYCLYL AND HETEROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-22 | — | — | US | disclosed |
| EP-4126849-A1 | N-(HETEROCYCLYL AND HETEROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021202775-A1 | N-(HETEROCYCLYL AND HETEROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025851-A1 | Modulators of BCL6 as Ligand Directed Degraders | BCL6, BCL6B, BCL3 | ALDH1A1 3481/4885ACHE 4717/4885NPC1 3285/4885 |
| US-20230192659-A1 | N-(HETEROCYCLYL AND HETEROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS | SSTR4, SSTR3, SSTR1 | ALDH1A1 4134/4885ACHE 2239/4885NPC1 2538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.